Tag: 上海品茶网EEB

Pharmalittle: Trump leaves Democrats confused over drug pricing; Vertex dismisses U.K. licensing threat

first_img Log In | Learn More What’s included? By Ed Silverman Feb. 6, 2019 Reprints Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Remember that no prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch …President Trump left Congress a two-syllable mandate on prescription drug pricing: “Do more.” To some Democrats, the words presented an open invitation to collaborate. Others were left confused as to what, exactly, the White House wants, STAT tells us. Following the State of the Union address, the divide among Democrats was apparent — between lawmakers prepared to cross partisan lines, those entirely opposed to Trump’s approach, and others waiting for more detailed direction. Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Tags cancerdrug pricingfinancepharmalittleSTAT+ GET STARTED Pharmalittle: Trump leaves Democrats confused over drug pricing; Vertex dismisses U.K. licensing threat What is it? Pharmalot center_img Alex Hogan/STAT Ed Silverman [email protected] STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. About the Author Reprints Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. @Pharmalot Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTEDlast_img read more

Read More